Summary of Conference Call on Biopharmaceutical Company Company and Industry Overview - **Company**: Biopharmaceutical Company (生物股份) - **Industry**: Animal Vaccines, specifically focusing on African Swine Fever (ASF) vaccines Key Points and Arguments Clinical Progress and Results - The clinical progress of the ASF subunit vaccine is on track, achieving a 100% protection rate in the first round of challenge tests, exceeding the Ministry's standard of 80% [2][4] - A second challenge test is scheduled for April 12, 2026, with results expected in early May 2026. If successful, the company could receive a temporary production license by Q3 2026 [4][11] Competitive Advantages - Biopharmaceutical Company is the only GCP (Good Clinical Practice) contractor for the ASF vaccine, providing a competitive edge with a validated process and a potential market exclusivity of 1 to 1.5 years [2][6] - The company has invested nearly 600 million yuan in the project, including 200 million yuan for a P3 laboratory and another 200 million yuan for the production line, establishing high entry barriers in the industry [2][7] Production Capacity and Pricing - The company has established a production line capable of producing 300 million doses annually, with an expected price of around 25 yuan per dose and a target market penetration of 20%-30% [2][5] Technical Coverage and Efficacy - The subunit vaccine is effective against both type I and type II ASF strains, with a reserve of mRNA vaccine technology soon to be submitted for approval [2][8] - The challenge dose for the vaccine was set at 8,000 HAD, and the vaccine has shown effectiveness against the majority of circulating strains [8] Market Dynamics and Future Outlook - The ASF vaccine market may face competition in the future, but any new entrants are expected to emerge in two to three years. The market will likely be shared among a few companies, with a stable demand from China's 700 million pigs [9][10] - Even if prices decrease due to competition, the company anticipates maintaining profit margins through economies of scale as production volumes increase [10] Customer Engagement and Market Acceptance - The company is engaging with both large-scale farms and smallholders, with notable interest from major players like Zhengda Group. The involvement of significant shareholders indicates strong market demand for the vaccine [10] Upcoming Milestones - Key upcoming milestones include the second challenge test on March 12, 2026, with results expected in May 2026. Following successful results, the company anticipates receiving a temporary production license by Q3 2026 [11]

Summary of the Conference Call for Bio Co., Ltd. Industry and Company Overview - The conference call focused on Bio Co., Ltd., specifically its developments in the African Swine Fever (ASF) vaccine sector, which is a critical area in the animal health industry. Key Points and Arguments 1. **Positive Results from ASF Vaccine Trials** Bio Co., Ltd. reported successful results from its subunit ASF vaccine attack experiment, where no deaths occurred among the immunized group under an 8,000 HAD virus attack, indicating a high protection rate. This sets a solid foundation for subsequent clinical trials and approvals [2][3]. 2. **Upcoming Clinical Trials** The company plans to conduct a second attack experiment on April 12, aiming to verify the vaccine's effectiveness throughout its lifecycle. The completion of the second clinical trial is expected by late May or early June [2][3]. 3. **Market Approval Timeline** If the results are favorable, the China National Center for Animal Health (CNCA) may participate in the review process, potentially accelerating the approval timeline. The company anticipates obtaining a temporary production license by mid to late 2026, allowing for large-scale production [2][3]. 4. **Pricing Strategy** The initial pricing for the ASF vaccine is set at 25 RMB per dose, which balances affordability for farmers and the technological uniqueness of the product. The expected gross margin is projected to exceed 50%, indicating strong profitability potential [2][5]. 5. **Competitive Advantages** Bio Co., Ltd. is currently the only company certified by the Chinese Academy of Sciences to conduct clinical trials for the ASF vaccine, providing a significant competitive edge. The involvement of CNCA in the process is expected to expedite market entry [2][6][7]. 6. **Collaboration in Vietnam** The company is collaborating with local firms in Vietnam to promote the ASF vaccine, addressing the issue of local pig populations infected with recombinant viruses. They expect to obtain production licenses within six months and begin sales within 18 months [2][9]. 7. **Future Developments in mRNA Vaccines** Bio Co., Ltd. is also working on an mRNA vaccine for feline infectious peritonitis, projected to be launched domestically by 2028. The company is collaborating with two major U.S. pharmaceutical companies, utilizing a revenue-sharing model that could yield significant returns [3][10]. 8. **Overall Business Outlook for 2026** The company anticipates explosive growth in the ruminant service sector in 2026, driven by the ASF vaccine's market entry. The poultry business remains stable, and overall, the company expects positive trends across its various segments [3][12]. Additional Important Information - The company is currently focusing on testing the vaccine primarily for piglets, with plans for further discussions regarding its application for sows based on feedback from breeding farms [5]. - The competitive landscape includes other companies like Jinyu Biological, which has completed clinical trials but may face delays in large-scale production due to additional trial requirements [8]. - The fourth quarter's specific data on other products like swine foot-and-mouth disease vaccines is pending, but the ASF vaccine is expected to drive sales of existing products [11].

Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [9][66]. Core Insights - The swine industry is entering an accelerated phase of capacity reduction, presenting opportunities at the bottom of the market. Regulatory measures are being reinforced to control pig prices, with expectations of a gradual adjustment rather than aggressive interventions. The focus is on low-cost performance and dividend increases for value reassessment, particularly for leading companies like Muyuan Foods and WH Group [1][14]. - The poultry sector is expected to see improvements in fundamentals, with historical highs in the number of breeding stock updates. The price dynamics are currently low, but there is potential for marginal changes in the cycle. Recommended companies include Shennong Development and Lihua Agricultural [2][28]. - The animal health sector is advancing with the clinical trials of the African swine fever subunit vaccine, which has received approval for clinical trials. The likelihood of domestic vaccine market entry is increasing, with recommended companies including BioFeng and Kexin Biological [3][6]. - The pet industry continues to grow rapidly, with significant improvements in profitability. Recommended companies in the pet food sector include GuaiBao Pet and ZhongChong Co., while in the pet medical sector, RuiPu Biological is highlighted [9][60]. Summary by Sections Swine Industry - The swine industry is experiencing a capacity reduction phase, with regulatory measures aimed at stabilizing prices. The average price of pigs in December 2025 was 11.59 CNY/kg, with a slight month-on-month decrease. The number of breeding sows has decreased by 1.1% month-on-month and 2.1% year-on-year [13][14]. - Recommended companies include Muyuan Foods and WH Group, with additional attention on Dekang Agriculture, Shennong Group, and Juxing Agriculture [1][14]. Poultry Industry - The poultry sector is seeing a potential improvement in fundamentals, with breeding stock updates reaching historical highs. The average price for broiler chickens was 3.9 CNY/jin, with a slight increase [26][28]. - Recommended companies are Shennong Development and Lihua Agricultural [2][28]. Animal Health - The animal health sector is focused on the progress of the African swine fever vaccine trials, with the first round of trials proceeding as planned. The second round is set to begin by the end of March 2026 [3][6]. - Companies to watch include BioFeng, Kexin Biological, and RuiPu Biological [6]. Pet Industry - The pet market is projected to reach a scale of 300.2 billion CNY in 2024, with a year-on-year growth of 7.5%. The average annual spending per pet dog is 2,961 CNY, while for cats, it is 2,020 CNY [59][60]. - Recommended companies include GuaiBao Pet, ZhongChong Co., and Peidi Co. in the pet food sector, and RuiPu Biological in the pet medical sector [9][60]. Feed Industry - The feed industry is experiencing price fluctuations, with the price of feed for fattening pigs at 3.34 CNY/kg, showing a month-on-month increase [47][48]. - Recommended companies include Haida Group and HeFeng Co. [48]. Planting Industry - Grain prices have increased year-on-year, with corn prices at 2,250 CNY/ton, showing a 10.5% increase compared to the previous year [41][46]. - Companies to focus on include SuKan Agricultural Development, LongPing High-Tech, and DengHai Seeds [7][46].

Group 1 - The company has submitted a clinical trial application for its African swine fever subunit vaccine developed in collaboration with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences [2] - The company will fulfill its information disclosure obligations in a timely manner if the relevant matters meet the standards for information disclosure [2]

Core Viewpoint - The significant upward revision of profit forecasts for Shenghua Co. (600201.SH) by Kaiyuan Securities reflects a strong confidence in the company's growth prospects, particularly driven by the development of the African swine fever vaccine [1][6]. Group 1: Profit Forecast Adjustments - In late October 2025, Kaiyuan Securities provided a cautious profit forecast for Shenghua Co. for 2025-2027, estimating net profits of 1.88 billion, 3.52 billion, and 5.08 billion respectively [2]. - By January 8, 2026, the profit forecast for 2026 was dramatically increased to 7.12 billion, nearly doubling the previous estimate, while the 2027 forecast rose by over 138% to 12.11 billion [2]. Group 2: Key Drivers of Growth - The major adjustment in profit forecasts is primarily attributed to the unexpected progress in the research and development of the African swine fever subunit vaccine, with Shenghua Co. being the first and only company in China approved for clinical trials [3]. - The vaccine is expected to create an incremental market size of approximately 84 billion in China, positioning Shenghua Co. as a significant beneficiary due to its first-mover advantage [3]. Group 3: Traditional Business Performance - Besides the potential of the African swine fever vaccine, Shenghua Co.'s traditional business is also showing steady growth, with a 50% year-on-year increase in sales of foot-and-mouth disease vaccines in the first three quarters of 2025 [4]. - Other vaccine products, including those for ruminants, poultry, and pets, are also experiencing strong growth, supported by a robust investment in R&D, which accounted for 13.51% of revenue in the first half of 2025 [4].

Core Viewpoint - The major shareholder of Jinyu Biotechnology Co., Ltd. has initiated a share buyback, reflecting confidence in the company's prospects for its African swine fever vaccine development [1][3]. Group 1: Shareholder Actions - As of January 6, 2026, the major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., has completed its first share buyback, acquiring 614,600 A-shares, which represents 0.0553% of the total share capital, with a total transaction amount of approximately 9.83 million yuan [1]. - The buyback plan was announced on December 24, 2025, with a commitment to purchase shares worth between 50 million and 100 million yuan over the next 12 months [1]. Group 2: Vaccine Development - The urgency for vaccine development is underscored by the ongoing severe African swine fever epidemic, with over 8,000 reported cases globally from January to September 2025 and more than 2 million livestock deaths since 2022 [2]. - The company is collaborating with the Chinese Academy of Sciences to develop a subunit vaccine for African swine fever, which is expected to provide critical technical support for epidemic control and significantly reduce losses in the breeding sector [2]. Group 3: Research and Production Capabilities - The company has established a biosafety level 3 laboratory to support key research activities, including antigen screening and efficacy validation for the vaccine [3]. - The vaccine has received clinical trial approval from the Ministry of Agriculture and Rural Affairs, with the first clinical trial phase completed and the efficacy evaluation stage currently underway [3]. - The company has prepared a GMP-compliant production facility for the vaccine, ensuring readiness for industrialization and quality control [3]. Group 4: Financial Performance - The company has maintained over 10% of its revenue for R&D investment over the past six years, indicating a strong commitment to innovation [4]. - For the first three quarters of 2025, the company reported revenues of 1.042 billion yuan, a year-on-year increase of 7.38%, with a significant profit growth of 116.40% in the third quarter [4].

Core Viewpoint - The company, Jinyu Biotechnology Co., Ltd., reported a revenue of 1.04 billion yuan in the first three quarters of 2023, reflecting a year-on-year growth of 7.38%, and a net profit of 161 million yuan [2]. Group 1: Financial Performance - In Q3 2023, the company achieved a revenue of 423 million yuan, representing a year-on-year increase of 17.76%, and a net profit of 101 million yuan, which is a significant growth of 116.40% [3]. - For the first three quarters of 2023, the company's R&D expenses amounted to 96.01 million yuan, showing a year-on-year increase of 9.08% [4]. Group 2: Product and Market Strategy - The company focuses on the research, production, and sales of veterinary biological products, with a product range that includes over a hundred types of vaccines for pigs, poultry, ruminants, and pets [3]. - The company is implementing a "big product, big customer" strategy, achieving breakthroughs in the development of major vaccines such as foot-and-mouth disease, African swine fever, and feline infectious peritonitis [3]. - The company is expanding its international presence, with products registered and sold in countries like Pakistan and Vietnam, and plans to enhance penetration in Central Asia, Southeast Asia, and Africa [4]. Group 3: Innovation and Future Plans - The company emphasizes technological innovation to address industry challenges, with ongoing development of innovative products like the African swine fever subunit vaccine and mRNA vaccine for feline infectious peritonitis [3]. - The company aims to transition from single product sales to a model that includes "professional services + comprehensive solutions," focusing on deep customer engagement [5]. - The pet business is identified as a significant growth area, with plans to establish a pet marketing ecosystem and expand into health products and pharmaceuticals [5].

Market Review - The agricultural, forestry, animal husbandry, and fishery sector has outperformed the benchmark index since the beginning of 2025, with an absolute return of +24.66%, surpassing the CSI 300 index by 10.47 percentage points [10][17][18] - The sector's index has increased by 18.4% over the past year, outperforming the CSI 300 index by 0.96 percentage points [14] Swine Breeding - The breeding capacity of sows is gradually declining, with a total of 39.9 million sows recorded by the end of October 2025, a year-on-year decrease of 2.04% [27][24] - The average price of live pigs in October 2025 was 11.52 yuan/kg, reflecting a month-on-month decline of 11.46% and a year-on-year drop of 34.77% [29] - The swine breeding industry is currently facing losses, with theoretical profits for self-bred pigs averaging -209.67 yuan/head in October 2025, marking a significant decline from previous months [36][41] - The market share of the top eight listed pig companies has increased from 4.6% in 2017 to 21.2% by the third quarter of 2025, indicating a trend towards industry consolidation [37][41] Animal Health - The animal health market in China has shown steady growth, with sales increasing from 47.23 billion yuan in 2016 to 69.65 billion yuan in 2023, reflecting a compound annual growth rate of 5.71% [45][46] - The introduction of new products and the expansion of demand are driving the growth of the animal health industry, particularly with the anticipated market expansion following the launch of African swine fever vaccines [51][52] - The market for companion animal health products is also growing, with the pet medical market expected to reach approximately 84 billion yuan in 2024, driven by increased spending on veterinary services [56] Seed Industry - The seed industry is experiencing a transformation due to new regulations and policies, with significant investment opportunities arising from the commercialization of biotechnology [4][19] - The market for genetically modified corn is projected to expand, with companies in the sector expected to benefit from increased industry concentration and profitability [18][19] Pet Food - China's pet food market is projected to continue growing, benefiting from demographic changes and rising living standards, with significant potential for domestic brands to capture market share [5][59] - The market for pet food exports is expected to maintain year-on-year growth in 2025, reflecting the increasing demand for high-quality pet products [5][59] - The pet food industry remains fragmented, with ongoing trends towards domestic substitution and increased online sales [5][59]

Core Viewpoint - The company reported a significant rebound in performance in Q3 2025, despite facing pressures in the animal health industry due to market competition and price declines in core products [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.042 billion yuan, a year-on-year increase of 7.38%, and a net profit attributable to shareholders of 161 million yuan [1]. - In Q3 2025 alone, the company recorded revenue of 423 million yuan, up 17.76% year-on-year, and a net profit of 101 million yuan, representing a substantial increase of 116.40% [1]. Market Position and Strategy - The company maintained a strong market share in core products like foot-and-mouth disease vaccines, despite intense competition and price pressures [2]. - The pet and international segments have shown remarkable performance, becoming key growth drivers for the company [2]. - The company is transitioning from pure product sales to a model that includes professional services and comprehensive solutions, enhancing customer loyalty and ensuring healthy cash flow through strict credit policies [2]. Research and Development - The company invested 96.015 million yuan in R&D in the first three quarters, reflecting a year-on-year increase of 9.08% [2]. - The company has successfully diversified its product structure, reducing reliance on single products and achieving significant sales growth in core vaccines [3]. - The company is focusing on key products like the African swine fever vaccine, which is seen as a critical opportunity in the animal health industry [3]. Technological Advancements - The company established the world's first animal mRNA vaccine production facility, which is a core component of its technological advantage [4]. - The company has multiple mRNA vaccine projects in various stages, including the world's first mRNA vaccine for feline infectious peritonitis, which is expected to generate over 1 billion yuan in sales in its first year [4]. Future Growth Strategy - The company aims to shift from reliance on single products to a multi-business model, with three main growth engines: expanding the pet business, international market penetration, and continuous R&D breakthroughs [5].